Loading...
•
Sep 30, 2020
Corbus Pharmaceuticals Q3 2020 Earnings Report
Reported a net loss for the third quarter of 2020 and provided corporate updates.
Key Takeaways
Corbus Pharmaceuticals reported a net loss of $34.9 million for the third quarter of 2020. The company is focusing on its lenabasum dermatomyositis program and preclinical pipeline, with expectations to extend its cash runway through cost savings.
Company is focused on lenabasum dermatomyositis program and preclinical pipeline.
Restructuring significantly improved cash runway.
Plan to shorten the DETERMINE Phase 3 dermatomyositis study to 28 weeks to accelerate topline data readout to the second quarter of 2021.
Working with systemic sclerosis and cystic fibrosis experts to further analyze the data and potentially explore paths forward in these programs.